On June 2, 2021, Protalix and development partner, Chiesi Global Rare Diseases, provided an update regarding clinical development of Protalix’ candidate pegunigalsidase alfa (PRX-102) and hosted a ...
Investors in Protalix BioTherapeutics, Inc. (NYSE:PLX) need to pay close attention to the stock based on moves in the options ...
Double-digit gains across a session or two in small cap biotech aren’t all that rare. Low floats can combine with speculative volume inflow to push a company’s capitalization well into a spike, and ...
Noteworthy events for the week of Feb. 4 - 10 for healthcare investors: Monday (2/5): WORLDSymposium, San Diego, CA (four days). Protalix BioTherapeutics (NYSE:PLX): data on PRX-102 in Fabry disease.
HAIFA, Israel, June 25, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today reported positive data from ...
On June 2, 2021, Protalix (NYSE:PLX) and development partner, Chiesi Global Rare Diseases, provided an update regarding clinical development of Protalix’ candidate pegunigalsidase alfa (PRX-102) and ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback